Mendoza-Guevara Citlali Cecilia, Martinez-Escobar Alejandro, Ramos-Godínez María Del Pilar, Muñoz-Medina José Esteban, Ramon-Gallegos Eva
Laboratorio de Citopatología Ambiental, Departamento de Morfología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (IPN), Ciudad de México 07738, Mexico.
Laboratorio de Microscopía Electrónica, Instituto Nacional de Cancerología (INCAN), Ciudad de México 14080, Mexico.
Pharmaceuticals (Basel). 2025 May 5;18(5):683. doi: 10.3390/ph18050683.
: Gene therapy has emerged as a promising strategy for treating a wide range of diseases. However, a major challenge remains in developing efficient and safe delivery systems for genetic material. Nanoparticles, particularly chitosan nanoparticles (CNPs), have gained significant attention as a potential solution. This study focuses on designing a SARS-CoV-2 plasmid DNA (pDNA) conjugated with CNPs and evaluating its in vitro delivery efficiency. : The Omicron Spike DNA sequence was inserted into the pIRES2-eGFP expression vector, and CNPs were synthesized with optimized physicochemical properties to enhance stability, cellular uptake, and transfection efficiency. The conjugate was characterized using UV-Vis, FT-IR, DLS, and TEM techniques. Transfection efficiency was assessed and compared to the commercially available TurboFect reagent as a control. : CNPs-pDNA polyplexes with an average size of 159.0 ± 33.1 nm (TEM), a zeta potential of +19.7 ± 0.3 mV, and 100% ± 0.0 encapsulation efficiency were developed as a non-viral delivery system. CNPs efficiently serve as a delivery vehicle for the constructed pDNA without altering cell morphology, achieving transfection efficiencies of 62-74%, compared to 55-70% for TurboFect. Furthermore, RT-qPCR confirmed the expression of Spike mRNA, and Western blot assays validated the expression of Spike protein. Notably, Spike protein expression from CNPs was found to be two-fold higher than the control at 96 h post-transfection. : These findings suggest that CNPs are a promising and versatile platform for delivering genetic material. Importantly, this study highlights the intrinsic properties of chitosan, without the use of additional ligands, as a key factor in achieving efficient gene delivery.
基因治疗已成为治疗多种疾病的一种有前景的策略。然而,在开发用于遗传物质的高效且安全的递送系统方面,仍然存在重大挑战。纳米颗粒,特别是壳聚糖纳米颗粒(CNPs),作为一种潜在的解决方案已受到广泛关注。本研究聚焦于设计一种与CNPs共轭的新型冠状病毒2型质粒DNA(pDNA),并评估其体外递送效率。
将奥密克戎刺突蛋白DNA序列插入pIRES2-eGFP表达载体中,并合成具有优化物理化学性质的CNPs,以提高稳定性、细胞摄取和转染效率。使用紫外可见光谱、傅里叶变换红外光谱、动态光散射和透射电子显微镜技术对共轭物进行表征。评估转染效率,并与市售的TurboFect试剂作为对照进行比较。
开发了一种平均粒径为159.0±33.1nm(透射电子显微镜)、ζ电位为+19.7±0.3mV且包封率为100%±0.0的CNPs-pDNA多聚体作为非病毒递送系统。CNPs有效地作为构建的pDNA的递送载体,而不改变细胞形态,实现了62-74%的转染效率,相比之下TurboFect为55-70%。此外,逆转录定量聚合酶链反应证实了刺突蛋白mRNA的表达,蛋白质免疫印迹分析验证了刺突蛋白的表达。值得注意的是,在转染后96小时,发现CNPs的刺突蛋白表达比对照高两倍。
这些发现表明,CNPs是一种有前景且通用的遗传物质递送平台。重要的是,本研究强调了壳聚糖的固有特性,无需使用额外的配体,是实现高效基因递送的关键因素。